News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40 Results
Type
Article (6)
Press Release (34)
Section
Business (16)
Deals (4)
Drug Development (6)
Job Trends (2)
News (21)
Tag
Alliances (2)
Best Places to Work (1)
Cancer (1)
Clinical research (3)
Earnings (1)
Events (9)
IPO (2)
Job creations (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (2)
NextGen Class of 2024 (1)
People (9)
Phase I (3)
Phase II (3)
Preclinical (2)
Real estate (1)
Startups (3)
Date
Last 365 days (3)
2024 (2)
2023 (7)
2022 (5)
2021 (12)
2019 (1)
2018 (3)
2017 (3)
2016 (5)
2015 (2)
Location
Asia (1)
Canada (1)
Europe (3)
40 Results for "oncoresponse".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, announced the appointment of Carol Gallagher, Pharm.D., as an Independent Director to its Board of Directors.
September 6, 2023
·
2 min read
Drug Development
OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
OncoResponse today announced the dosing of the first participant in the Phase 1/2 trial of OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression.
November 29, 2023
·
3 min read
BioForest
OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy
OncoResponse today announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
May 18, 2023
·
3 min read
BioForest
OncoResponse to Present at 41st Annual J.P. Morgan Healthcare Conference
OncoResponse announced that Clifford Stocks, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11 a.m. PST.
January 5, 2023
·
1 min read
BioForest
OncoResponse Presents at AACR 2023 Annual Meeting Preclinical Data Highlighting Dual Antagonist Antibodies Targeting both LILRB1 and LILRB2
OncoResponse today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.
April 19, 2023
·
3 min read
BioForest
OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)
OncoResponse today announced a poster presentation at the upcoming American Association for Cancer Research Annual Meeting being held April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.
March 15, 2023
·
2 min read
Drug Development
OncoResponse IDs Elite Cancer Responders’ Antibodies to Make IO More Effective
OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.
May 9, 2022
·
4 min read
·
Gail Dutton
BioForest
OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemiplimab) in Patients with Advanced Cancer
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo® (cemiplimab).
September 7, 2022
·
3 min read
BioForest
OncoResponse to Present at Upcoming Investor Conferences
OncoResponse today announced that Clifford Stocks, Chief Executive Officer, will participate in two upcoming investor conferences.
November 22, 2021
·
1 min read
Drug Development
OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022
OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Responders, today announced preclinical data on immuno-oncology candidates OR2805 and OR502 presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
November 11, 2022
·
3 min read
1 of 4
Next